Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.56. Hemispherx BioPharma shares last traded at $0.48, with a volume of 215,153 shares traded.
Hemispherx BioPharma Stock Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Stories
- Five stocks we like better than Hemispherx BioPharma
- When to Sell a Stock for Profit or Loss
- Comprehensive PepsiCo Stock Analysis
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How is Compound Interest Calculated?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
